The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What updates are there on the VIALE-C trial for acute myeloid leukemia patients?
Andrew Wei
July 16, 2020
During the 25th Congress of the European Hematology Association (EHA), KnowAML spoke to Andrew Wei, The Alfred, Melbourne. We asked: What updates are there on the VIALE-C trial, and what do they mean for patients with acute myeloid leukemia? Elderly patients with acute myeloid leukemia are often ineligible for intensive therapy, and are mostly treated at lower doses with a chemotherapy agent called cytarabine (Ara-C). The VIALE-C study is a phase III clinical trial designed with an aim to improve patient outcomes to therapy and expand the treatment options for elderly patients with acute myeloid leukemia. Venetoclax is a newer treatment, which causes death of leukemic cells and is more targeted than conventional chemotherapy. The VIALE-C trial is looking at whether the addition of venetoclax to low-dose Ara-C could improve elderly patients responses to therapy. Patient response rates were substantially higher when treated with venetoclax + Ara-C compared with Ara-C + a placebo tablet.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
